ARYx (ARYX) Announces Successful Study Results But Procter & Gamble (PG) Ends Collaboration
More News related to ARYX
- ARYx Therapeutics Appoints Amgen Executive to Board of Directors
- ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
- ARYx Reports Second Quarter 2008 Financial Results
- ARYx Therapeutics Schedules Second Quarter 2008 Results and Earnings Call
- Pre-Open Movers 7/3: NVIDIA (NVDA) Clobbered On Warning, Chindex (CHDX) Up on China Approvals
ARYx Therapeutics, Inc., (NASDAQ: ARYX) announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505. The overall results of a Thorough QT (TQT) study designed to demonstrate whether electrocardiographic effects are seen at therapeutic and supra therapeutic doses and conducted under a collaboration agreement with Procter & Gamble Pharmaceuticals (P&G) were negative, supporting the favorable cardiac safety profile of the agent. ATI-7505 is a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia.
Seperatly, ARYx Therapeutics announced that Procter & Gamble Pharmaceuticals, Inc. (P&G) has utilized a one-time thirty day cancellation option linked to the completion of a Thorough QT (TQT) study to end the collaboration agreement between the companies covering the late-stage development and commercialization of ATI-7505, a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia.
The company said, "We have been informed by P&G their decision is based on their view of certain commercial and technical criteria, and that the program no longer fits into their future plans."
Related Categories
FDAHot List
Stocks Mentioned
-0.22Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
